High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Annals of Hematology

• Publication date

  2003-10-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00277-003-0710-5PMID 14551737
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fludarabine

  2012cited by this paper
• p53 abnormalities in splenic lymphoma with villous lymphocytes.

  2001cited by this paper
• Glucocorticoid hormones in the regulation of cell death.

  2000cited by this paper
• Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.

  2000cited by this paper
• Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.

  2000cited by this paper
• Genomic aberrations and survival in chronic lymphocytic leukemia.

  2000cited by this paper
• Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay

  1999cited by this paper
• Glucocorticoid induced apoptosis in leukemia.

  1999cited by this paper
• Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin

  1999cited by this paper
• Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia.

  1999cited by this paper
• Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay

  1999cited by this paper
• Modulations of glucocorticoid-induced apoptosis linked to the p53 deletion and to the apoptosis susceptibility gene Rapop1 (Radiation-induced apoptosis 1)

  1999cited by this paper
• Impairments in immune cell function in B cell chronic lymphocytic leukemia.

  1998cited by this paper
• Cell cycle regulation and apoptosis.

  1998cited by this paper
• p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.

  1998influential reference
• Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia

  1997cited by this paper
• p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis

  1997cited by this paper
• P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.

  1997influential reference
• Chlorambucil in chronic lymphocytic leukemia: mechanism of action.

  1996cited by this paper
• Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology.

  1996cited by this paper
• Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience.

  1996cited by this paper
• The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine

  1996cited by this paper
• P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance.

  1995cited by this paper
• Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.

  1995influential reference
• p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

  1995influential reference
• Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.

  1995cited by this paper
• Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.

  1994cited by this paper
• p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies

  1994cited by this paper
• The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.

  1994cited by this paper
• p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.

  1994influential reference
• p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

  1993cited by this paper
• Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages.

  1993cited by this paper
• Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.

  1993influential reference
• Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis.

  1992cited by this paper
• Fludarabine therapy in chronic lymphocytic leukemia (CLL).

  1988cited by this paper

• Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.

  2020cites this paper
• Individualized Tumor Response Testing in Leukemia and Lymphoma

  2019cites this paper
• 大剂量甲泼尼龙联合利妥昔单抗及新鲜冰冻血浆治疗伴有TP53基因异常的B细胞慢性淋巴增殖性疾病六例

  2019cites this paper
• 传统免疫化疗时代118例TP53基因异常慢性淋巴细胞白血病患者生存分析

  2019cites this paper
• A CASE REPORT OF EXTREMES: THE STRIKING EFFICACY OF VENETOCLAX AND HIGH DOSE METHYLPREDNISOLONE RESCUE IN CLL

  2018cites this paper
• Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy

  2018cites this paper
• The use of inexpensive broad spectrum lower toxicity therapeutics in chronic lymphocytic leukemia.

  2017cites this paper
• Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.

  2017cites this paper
• Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China

  2017cites this paper
• Targeted therapies for CLL: Practical issues with the changing treatment paradigm.

  2016cites this paper
• Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells

  2016cites this paper
• Chronic lymphocytic leukemia/small lymphocytic lymphoma

  2016cites this paper
• Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia

  2015cites this paper
• Compositions et procédés pour le traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk

  2015cites this paper
• Inhibiteurs de btk pour le traitement de tumeurs solides par modulation du micro-environnement tumoral

  2015cites this paper
• Hormonal therapy in oncology: a primer for the radiologist.

  2015cites this paper
• Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing

  2015cites this paper
• How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?

  2015cites this paper
• TP53 Mutation Analysis in Clinical Practice: Lessons From Chronic Lymphocytic Leukemia

  2014cites this paper
• Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art

  2014cites this paper
• The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia

  2014cites this paper
• Primary refractory T‐cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high‐dose methylprednisolone

  2014cites this paper
• Personalized medicine in CLL: current status and future perspectives.

  2014cites this paper
• A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53

  2014cites this paper
• Evidence-based Management of Newly Diagnosed Chronic Lymphocytic Leukemia

  2014cites this paper
• Improving Glucocorticoid Therapy in Chronic Lymphocytic Leukemia

  2013cites this paper
• FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA January 10 2013

  2013cites this paper
• The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia

  2013cites this paper
• high-risk chronic lymphocytic leukemia associated with marked clinical efficacy in refractory, genetically Flavopiridol administered using a pharmacologically derived schedule is

  2013cites this paper
• Approach to frontline therapy in elderly chronic lymphocytic leukemia patients

  2013cites this paper
• Chapter 5 TP 53 Aberrations in Chronic Lymphocytic Leukemia

  2013cites this paper
• promising therapeutic target disease progression in chronic lymphocytic leukemia and represents a B subunit Rel A is associated with in vitro survival and clinical κ The NF

  2013cites this paper
• Хронический лимфолейкоз высокого риска: история, определение, диагностика и лечениеХронический лимфолейкоз высокого риска: история, определение, диагностика и лечение

  2013cites this paper
• TP53 aberrations in chronic lymphocytic leukemia.

  2013cites this paper
• How I treat patients with relapsed chronic lymphocytic leukaemia

  2013cites this paper
• Targeting inflammatory pathways in chronic lymphocytic leukemia.

  2013cites this paper
• Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone

  2013cites this paper
• New Insights into Biology, Prognostic Factors, and Current Therapeutic Strategies in Chronic Lymphocytic Leukemia

  2013cites this paper
• The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia

  2012cites this paper
• Functional Role of Glycogen synthase Kinase-3β on Glucocorticoid-mediated signaling

  2012cites this paper
• Molecular mechanisms of apoptosis induced by dexamethasone in chronic lymphocytic leukemia

  2012cites this paper
• Therapeutic advancement of chronic lymphocytic leukemia

  2012cites this paper
• Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak

  2012cites this paper
• Treatment of relapsed or refractory chronic lymphocytic leukemia.

  2012cites this paper
• Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches.

  2012cites this paper
• Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status

  2012cites this paper
• The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry

  2012cites this paper
• Oral high-dose glucocorticoids and Ofatumumab in fludarabine-resistant Chronic Lymphocytic Leukemia

  2012cites this paper
• Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

  2012influential citation
• Current and Emerging Treatments for Chronic Lymphocytic Leukaemia

  2012cites this paper
• [Conventional therapeutic strategies for relapsed chronic lymphocytic leukemia].

  2012cites this paper
• Screening for cytotoxic compounds in poor-prognostic chronic lymphocytic leukemia.

  2012cites this paper
• Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.

  2012cites this paper
• Salvage therapy for relapsed chronic lymphocytic leukemia

  2011cites this paper
• Personalizing treatment for chronic lymphocytic leukemia

  2011cites this paper
• Lenalidomide in the treatment of chronic lymphocytic leukemia

  2011cites this paper
• The Rituximab in the Study of Relapsed Chronic Lymphocytic Leukemia

  2011cites this paper
• Lenalidomide in the treatment of chronic lymphocytic leukemia

  2011cites this paper
• Cancer Cell Culture

  2011cites this paper
• Differential Staining Cytotoxicity assay: a review.

  2011cites this paper
• Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia

  2011influential citation
• Treatment options for high-risk chronic lymphocytic leukaemia

  2011cites this paper
• What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?

  2011cites this paper
• Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach

  2011cites this paper
• The spectrum of use of rituximab in chronic lymphocytic leukemia

  2010cites this paper
• Rituximab in chronic lymphocytic leukemia.

  2010cites this paper
• High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.

  2010cites this paper
• Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.

  2010cites this paper
• Chronic lymphocytic leukemia.

  2010cites this paper
• Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia

  2010cites this paper
• New agents for the treatment of genetically high-risk chronic lymphocytic leukemia

  2010cites this paper
• The spectrum of use of rituximab in chronic lymphocytic leukemia

  2010cites this paper
• Chemoimmunotherapy of chronic lymphocytic leukemia

  2010cites this paper
• Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)

  2010cites this paper
• Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion

  2009cites this paper
• The role of alemtuzumab in chronic lymphocytic leukaemia patients with p53 defects

  2009cites this paper
• Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia

  2009cites this paper
• Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia

  2009cites this paper
• Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

  2009cites this paper
• Treatment of fludarabine‐refractory chronic lymphocytic leukemia

  2009cites this paper
• Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.

  2009cites this paper
• Flavopiridol (alvocidib) in chronic lymphocytic leukemia

  2009cites this paper
• RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

  2009cites this paper
• Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy

  2009cites this paper
• Flavopiridol in chronic lymphocytic leukemia: a concise review.

  2009cites this paper
• In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia – rolipram and prednisolone active in cells from patients with poor prognosis

  2009cites this paper
• Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.

  2009cites this paper
• The NF- (cid:1) B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target

  2008cites this paper
• Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog

  2008influential citation
• Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia

  2008cites this paper
• De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

  2008cites this paper
• The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.

  2008cites this paper
• Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.

  2008cites this paper
• High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy

  2008cites this paper
• Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

  2008cites this paper
• Chronic lymphocytic leukaemia.

  2008cites this paper
• Hypertension Congestive heart failure Peripheral vascular disease Cerebrovascular disease Angina Cardiac arrhythmia Myocardial infarction

  2008cites this paper
• hronic Lymphocytic Leukemia

  2007cites this paper
• Chronic Lymphocytic Leukemia: How to Assess Prognosis in 2007

  2007cites this paper
• Flavopiridol in Chronic Lymphocytic Leukemia

  2007cites this paper